Difference between revisions of "Template:Health risks in the conjugated estrogens and medroxyprogesterone acetate substudy of the Women's Health Initiative"

From blackwiki
Jump to navigation Jump to search
(Add Template:Improve documentation, date=March 2019: May need to mention it needs Template:Notelist and such.)
(Sources list: Use table footer element instead of table data cell for accessibility)
Line 29: Line 29:
 
|-
 
|-
 
| Other [[osteoporotic fracture]]s{{efn|name=not-gi}} || 0.77 (0.69–0.86) || 170 || 131
 
| Other [[osteoporotic fracture]]s{{efn|name=not-gi}} || 0.77 (0.69–0.86) || 170 || 131
|- class="sortbottom"
+
|-
| colspan="10" style="width: 1px;" | '''Sources:''' <ref name="EstraceLabel">{{cite web | url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/081295s014,084499s042,084500s044lbl.pdf | title=ESTRACE TABLETS, (estradiol tablets, USP) | author=Warner Chilcott | authorlink=Warner Chilcott | date=March 2005 | publisher=fda.gov | format=PDF | accessdate=27 November 2016 }}</ref><ref name="pmid12117397">{{cite journal | vauthors = Rossouw JE, Anderson GL, [[Ross Prentice|Prentice RL]], LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J | title = Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | journal = JAMA | volume = 288 | issue = 3 | pages = 321–33 | date = July 2002 | pmid = 12117397 | doi = 10.1001/jama.288.3.321 | url = }}</ref>
+
! colspan="10" style="width: 1px;" | '''Sources:''' <ref name="EstraceLabel">{{cite web | url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/081295s014,084499s042,084500s044lbl.pdf | title=ESTRACE TABLETS, (estradiol tablets, USP) | author=Warner Chilcott | authorlink=Warner Chilcott | date=March 2005 | publisher=fda.gov | format=PDF | accessdate=27 November 2016 }}</ref><ref name="pmid12117397">{{cite journal | vauthors = Rossouw JE, Anderson GL, [[Ross Prentice|Prentice RL]], LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J | title = Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | journal = JAMA | volume = 288 | issue = 3 | pages = 321–33 | date = July 2002 | pmid = 12117397 | doi = 10.1001/jama.288.3.321 | url = }}</ref>
 
|}<!--
 
|}<!--
  

Revision as of 11:37, 27 March 2019

Health risks in the CEEs/MPA substudy of the Women's Health Initiative

Event Relative Risk CEEs/MPA vs. placebo at 5.2 years (95% CI[note 1]) Placebo
(n = 8102)
CEEs/MPA
(n = 8506)
Absolute Risk per 10,000 Women-Years
Coronary heart disease events
( non-fatal myocardial infarction, death)
1.29 (1.02–1.63)
1.32 (1.02–1.72)
1.18 (0.70–1.97)
30
23
6
37
30
7
Invasive breast cancer[lower-alpha 1] 1.26 (1.00–1.59) 30 38
Stroke 1.41 (1.07–1.85) 21 29
Pulmonary embolism 2.13 (1.39–3.25) 8 16
Colorectal cancer 0.63 (0.43–0.92) 16 10
Endometrial cancer 0.83 (0.47–1.47) 6 5
Hip fracture 0.66 (0.45–0.98) 15 10
Death due to causes other than above 0.92 (0.74–1.14) 40 37
Global Index[lower-alpha 2] 1.15 (1.03–1.28) 151 170
Deep vein thrombosis[lower-alpha 3] 2.07 (1.49–2.87) 13 26
Vertebral fractures[lower-alpha 3] 0.66 (0.44–0.98) 15 9
Other osteoporotic fractures[lower-alpha 3] 0.77 (0.69–0.86) 170 131
Sources: [1][2]
Template documentation

Notes and references

  1. Warner Chilcott (March 2005). "ESTRACE TABLETS, (estradiol tablets, USP)" (PDF). fda.gov. Retrieved 27 November 2016.
  2. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (July 2002). "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial". JAMA. 288 (3): 321–33. doi:10.1001/jama.288.3.321. PMID 12117397.
  1. Includes metastatic and non-metastatic breast cancer with the exception of in situ breast cancer.
  2. A subset of the events was combined in a "global index", defined as the earliest occurrence of coronary heart disease events, invasive breast cancer, stroke, pulmonary embolism, endometrial cancer, colorectal cancer, hip fracture, or death due to other causes.
  3. 3.0 3.1 3.2 Not included in Global Index.

Template:Notefoot


Cite error: <ref> tags exist for a group named "note", but no corresponding <references group="note"/> tag was found, or a closing </ref> is missing